

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7907672

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
AMPHIVENA THERAPEUTICS, INC.	09/15/2022
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	AMP (AN ABC), LLC
<b>Street Address:</b>	C/O RAVIX GROUP, INC.
<b>Internal Address:</b>	226 AIRPORT PARKWAY, SUITE 400
<b>City:</b>	SAN JOSE
<b>State/Country:</b>	CALIFORNIA
<b>Postal Code:</b>	95110
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Patent Number:	10626190
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)832-7000
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 832-1754
<b>Email:</b>	patentdocketing@foleyhoag.com, kbigelow@foleyhoag.com
<b>Correspondent Name:</b>	FOLEY HOAG LLP
<b>Address Line 1:</b>	155 SEAPORT BOULEVARD
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02210-2600
<b>ATTORNEY DOCKET NUMBER:</b>	AJH-01703
<b>NAME OF SUBMITTER:</b>	KRISTIN BIGELOW
<b>SIGNATURE:</b>	/Kristin Bigelow/
<b>DATE SIGNED:</b>	04/18/2023
<b>Total Attachments: 7</b>	
source=AJH Executed Assignment - Amphi to AMP#page1.tif	
source=AJH Executed Assignment - Amphi to AMP#page2.tif	
source=AJH Executed Assignment - Amphi to AMP#page3.tif	
source=AJH Executed Assignment - Amphi to AMP#page4.tif	
source=AJH Executed Assignment - Amphi to AMP#page5.tif	

source=AJH Executed Assignment - Amphi to AMP#page6.tif

source=AJH Executed Assignment - Amphi to AMP#page7.tif

## PATENT ASSIGNMENT

This Patent Assignment (the "Assignment"), effective as of the 15th day of September, 2022, made by and between **Amphivena Therapeutics, Inc.**, a Delaware corporation ("ASSIGNOR"), and **AMP (an ABC), LLC**, a Delaware limited liability company ("ASSIGNEE").

WHEREAS, ASSIGNOR owns all rights, title, and interest in one or more inventions described in the patents and patent applications set forth in Exhibit A and, together with any divisional, continuation, continuation-in-part, reissue, re-examination, renewal or extension thereof and any patent issuing therefrom, and any corresponding patent, utility model, inventor certificate, registration or the like in any country of the world with respect to the foregoing, (the "Inventions"), having full right to convey its entire right, title and interest, both legal and equitable, in and to said inventions, free from all prior assignments, agreements, licenses, mortgages, security interests, or other encumbrances whatsoever; and

WHEREAS, ASSIGNEE is desirous of acquiring the entire right, title and interest in and to said Inventions and any and all patents to be obtained therefor;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR and ASSIGNEE hereby agree as follows:

ASSIGNOR does hereby sell, assign, transfer and set over unto ASSIGNEE, its successors and assigns, its entire right, title and interest throughout the world in and to: (i) said Inventions, and any form or embodiment thereof; (ii) all contracts, licenses, assignments and agreements of any kind or nature arising from such Inventions, including, without limitation all agreements with any inventor who has contributed to the Inventions; (iii) all proprietary rights pertaining to the Inventions including, without limitation, all rights arising from or relating to copyright, patent, trade secret, data and any rights arising under any laws now or hereinafter enacted relating to data protection, and all other proprietary rights of any kind or nature, now existing or hereafter created, however denominated, throughout the world; (iv) all claims and causes of action arising from or relating to the Inventions, including, without limitation, any and all claims or causes of action arising from or relating to the above described contracts and proprietary rights, whether arising in the past, present or future; (v) any application filed in any foreign country based on the Invention, including the right to file said foreign applications and claim priority under the provisions of any international convention or treaty; and (vi) the entire right, title and interest throughout the world in and to any and all patents or re-examinations or reissues or extensions thereof to be obtained in this or any foreign country upon said Inventions and any divisionals, continuations, continuations-in-part and renewals thereof, or substitute applications therefor, and all applications for industrial property protection, including, without limitation, all applications for patents, utility models, and designs which may hereafter be filed for an Invention described in any of the foregoing applications, including pending and abandoned applications, in any country or countries of the world, together with the right to file such applications and the right to claim for the same the priority rights derived from said applications under the Patent Laws of the United States, the International Convention for the Protection of Industrial Property, or any other international agreement or the domestic laws of the country in which any such application is filed, as may be

applicable. The undersigned hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns.

IN WITNESS WHEREOF, ASSIGNOR, by its duly authorized representative, have executed this Assignment under witness this 15th day of September, 2022.

AMPHIVENA THERAPEUTICS, INC.

By: *Michael J. Cronin*

Print Name: Michael J. Cronin

Title: Chief Executive Officer

*Lynn A. Cronin*  
Witness signature

Lynn A. Cronin  
Witness Name (please print)

IN WITNESS WHEREOF, ASSIGNEE, by its duly authorized representative, have executed this Assignment under witness this 15th day of September, 2022.

AMP (AN ABC), LLC

By: Rarix Group, Inc.  
A Delaware Corporation

Its Member

By: *Daniel Saccani*

Print Name: Daniel Saccani

Title: Principal

*Lynn A. Cronin*  
Witness signature

Lynn A. Cronin  
Witness Name (please print)

applicable. The undersigned hereby authorizes and requests the issuing authority to issue any and all patents on said application or applications to said ASSIGNEE or its successors and assigns.

IN WITNESS WHEREOF, ASSIGNOR, by its duly authorized representative, have executed this Assignment under witness this 15th day of September, 2022.

**AMPHIVENA THERAPEUTICS, INC.**

By: \_\_\_\_\_

Print Name: Michael J. Cronin

Title: Chief Executive Officer

\_\_\_\_\_  
Witness signature

\_\_\_\_\_  
Witness Name (please print)

IN WITNESS WHEREOF, ASSIGNEE, by its duly authorized representative, have executed this Assignment under witness this 15th day of September, 2022.

**AMP (AN ABC), LLC**

By: Ravix Group, Inc.

A Delaware Corporation

Its Member

By: \_\_\_\_\_

Print Name: Daniel Sacconi

Title: Principal

\_\_\_\_\_  
Witness signature

\_\_\_\_\_  
Witness Name (please print)

**EXHIBIT A****Patents and Patent Applications****BISPECIFIC CD33 AND CD3 BINDING PROTEINS**

<b>Country</b>	<b>Application Number</b>	<b>Application Status</b>	<b>Filing Date</b>
US	14/642497	Granted	09-Mar-2015
US	14/937494	Granted	10-Nov-2015
US	15/796556	Granted	27-Oct-2017
US	16/822528	Published	18-Mar-2020
WO	PCT/US15/38666	Nationalized	30-Jun-2015
EA	201790060	Granted	20-Jan-2017
CN	202110190211.6	Published	29-Jan-2021
CN	201580046856.5	Granted	01-Mar-2017
JP	2016-576032	Granted	28-Dec-2016
JP	2020-102787	Granted	28-May-2020
JP	2022-027453	Published	25-Feb-2022
KR	10-2017-7001723	Published	19-Jan-2017
AR	P150102079	Published	29-Jun-2015
AR	P210101013	Pending	11-Feb-2021
AU	2015284200	Granted	12-Jan-2017
AU	2020244593	Pending	01-Oct-2020
CA	2953992	Published	29-Dec-2016
HK	42022047505.7	Published	31-Jan-2022
HK	17110309.6	Granted	12-Oct-2017
MX	MX/a/2017/000187	Granted	04-Jan-2017
BR	BR112016030976-6	Published	17-Jan-2017
BR	BR122020026768-2	Pending	23-Dec-2020
MX	MX/a/2021/002912	Published	10-Mar-2021
US	62/019795	Expired	01-Jul-2014
US	62/111470	Expired	03-Feb-2015
IL	274892	Granted	25-May-2020
IL	283115	Pending	11-May-2021
IN	201617045072	Granted	30-Dec-2016
TW	104121393	Granted	01-Jul-2015
TW	110105389	Granted	01-Jul-2015
TW	111126359	Allowed	13-Jul-2022
EP	15815697.6	Granted	13-Jan-2017
EP	20216837.3	Published	23-Dec-2020
AT	15815697.6	Granted	13-Jan-2017

Country	Application Number	Application Status	Filing Date
BE	15815697.6	Granted	13-Jan-2017
CH	15815697.6	Granted	13-Jan-2017
DE	15815697.6	Granted	13-Jan-2017
DK	15815697.6	Granted	13-Jan-2017
ES	15815697.6	Granted	13-Jan-2017
FR	15815697.6	Granted	13-Jan-2017
IE	15815697.6	Granted	13-Jan-2017
IT	15815697.6	Granted	13-Jan-2017
NL	15815697.6	Granted	13-Jan-2017
SE	15815697.6	Granted	13-Jan-2017
GB	15815697.6	Granted	13-Jan-2017
SG	10201900015X	Pending	02-Jan-2019

#### METHODS OF USING BISPECIFIC CD33 AND CD3 BINDING PROTEINS

Country	Application Number	Application Status	Filing Date
US	15/578185	Granted	29-Nov-2017
US	16/989671	Published	10-Aug-2020
WO	PCT/US16/34479	Nationalized	26-May-2016
CN	2022103154129	Published	28-Mar-2022
EA	201792581	Published	21-Dec-2017
CN	2016800443990	Granted	29-Jan-2018
JP	2020-196489	Published	20-Nov-2020
KR	10-2017-7037643	Published	28-Dec-2017
AR	P160101561	Published	27-May-2016
AR	P210100954	Pending	01-Apr-2021
AU	2016271113	Allowed	22-Dec-2017
CA	2987037	Published	23-Nov-2017
HK	18112395.6	Published	27-Sep-2018
MX	MX/a/2017/015380	Published	29-Nov-2017
BR	BR112017025479-4	Published	03-Apr-2018
US	62/168641	Expired	29-May-2015
US	62/266438	Expired	11-Dec-2015
IL	255771	Granted	20-Nov-2017
IL	281970	Granted	01-Apr-2021
IN	201717045860	Published	20-Dec-2017
EP	16804079.8	Published	02-Jan-2018
SG	11201709579T	Granted	20-Nov-2017

**DOSING REGIMEN FOR CD3 BINDING PROTEINS**

<b>Country</b>	<b>Application Number</b>	<b>Application Status</b>	<b>Filing Date</b>
US	16/755426	Published	10-Apr-2020
WO	PCT/US18/55728	Nationalized	12-Oct-2018
JP	2020-542045	Published	10-Apr-2020
US	62/571755	Expired	12-Oct-2017
US	62/571767	Expired	12-Oct-2017
EP	18865621.9	Published	12-May-2020

**CD33×CD3 BINDING PROTEINS FOR TREATING INFLAMMATORY CONDITIONS AND DISEASES**

<b>Country</b>	<b>Application Number</b>	<b>Application Status</b>	<b>Filing Date</b>
US	17/284730	Published	12-Apr-2021
WO	PCT/US19/55930	Nationalized	11-Oct-2019
US	62/745247	Expired	12-Oct-2018
EP	19871960.1	Published	11-May-2021

**HOMODIMERIC, TRISPECIFIC, MULTIVALENT BINDING PROTEINS AND METHODS OF USE**

<b>Country</b>	<b>Application Number</b>	<b>Application Status</b>	<b>Filing Date</b>
US	63/274556	Pending	02-Nov-2021

**SINGLE CHAIN, BISPECIFIC, MULTIVALENT BINDING PROTEINS AND METHODS OF USE**

<b>Country</b>	<b>Application Number</b>	<b>Application Status</b>	<b>Filing Date</b>
US	63/274559	Pending	02-Nov-2021

**DOSING OF BISPECIFIC T CELL ENGAGER**

<b>Country</b>	<b>Application Number</b>	<b>Application Status</b>	<b>Filing Date</b>
US	16/888427	Published	29-May-2020
WO	PCT/US20/35373	Nationalized	29-May-2020
US	62/853802	Expired	29-May-2019
US	62/931742	Expired	06-Nov-2019
EP	20746424.9	Published	03-Jan-2022



ASSESSMENT OF CANCERS FOR TREATMENT WITH A CD33/CD3 BISPECIFIC T  
CELL ENGAGER

Country	Application Number	Application Status	Filing Date
WO	PCT/US21/58254	Published	05-Nov-2021
US	63/110011	Expired	05-Nov-2020

DOSING OF BISPECIFIC T CELL ENGAGER

Country	Application Number	Application Status	Filing Date
WO	PCT/US22/24063	Pending	08-Apr-2022
US	63/173224	Expired	09-Apr-2021
TW	111113549	Pending	08-Apr-2022